CEBPA and hepatocellular carcinoma: Previous self‐amplifying RNA vaccines against influenza A virus haemagglutinin and Toxoplasma gondii NTPase‐II have induced cellular and humoral immunogenicity in mice,71, 72 and a first‐in‐class clinical trial using self‐amplifying RNA against hepatocellular carcinoma encoding the transcription factor C/EBP‐α demonstrated acceptable safety and tolerability.73